A role of novel serpin maspin in tumor progression: The divergence revealed through efforts to converge

Journal of Cellular Physiology

Volumn 209, Issue 3, 2006, Pages 631-635

  Sheng, Shijie ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 1; MASPIN; SERINE PROTEINASE INHIBITOR; UROKINASE RECEPTOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CANCER GROWTH; CELL SURFACE; ENZYME INHIBITION; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN STRUCTURE; SHORT SURVEY;

DISEASE PROGRESSION; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HISTONE DEACETYLASES; HUMANS; NEOPLASMS; RECEPTORS, CELL SURFACE; SERPINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 33750517528     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20786     Document Type: Short Survey

References (70)

1. Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D, Rabbani SA. 1994. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54(9):2372-2377.
2. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. 2003. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 63(7):1684-1695.
3. Askew YS, Pak SC, Luke CJ, Askew DJ, Cataltepe S, Muls DR, Kato H, Lehoczky J, Dewar K, Birren B, Silverman GA. 2001. SERPINB12 is a novel member of the human ov-serpin family that is widely expressed and inhibits trypsin-like serine proteinases. J Biol Chem 276(52):49320-49330.
4. Bailey CM, Khalkhali-Ellis Z, Kondo S, Margaryan NV, Seftor RE, Wheaton WW, Amir S, Pins MR, Schutte BC, Hendrix MJ. 2005. Mammary serine protease inhibitor (Maspin) binds directly to interferon regulatory factor 6: Identification of a novel serpin partnership. J Biol Chem 280(40):34210-34217.
5. Bajou K, Noel A, Gerard RD. Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM. 1998. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4(8):923-928.
6. Bandyopadhyay D, Mishra A, Medrano EE. 2004. Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res 64(21):7706-7710.
7. Barsky SH, Doberneck SA, Sternlicht MD, Grossman DA, Love SM. 1997. 'Revertant' DCIS in human axillary breast carcinoma metastases. J Pathol 183(2):188-194.
8. Bartuski AJ, Kamachi Y, Schick C, Overhauser J, Silverman GA. 1997. Cytoplasmic antiproteinase 2 (P18) and bomapin (PI10) map to the serpin cluster at 18q21.3. Genomics 43(3):321-328.
9. Behrendt N, List K, Andreasen PA, Dano K. 2003. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: Rescue of activity through reciprocal pro-enzyme activation. Biochem J 371(Pt 2):277-287.
10. Benarafa C, Remold-O'Donnell E. 2005. The ovalbumin serpins revisited: Perspective from the chicken genome of clade B serpin evolution in vertebrates. Proc Natl Acad Sci USA 102(32):11367-11372.
11. Biliran H, Jr., Sheng S. 2001. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res 61(24):8676-8682.
12. Blacque OE, Worrall DM. 2002. Evidence for a direct interaction between the tumor suppressor serpin, maspin, and types I and III collagen. J Biol Chem 277(13):10783-10788.
13. Blasi F, Carmeliet P. 2002. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 3(12):932-943.
14. Blasi F, Behrendt N, Cubellis MV, Ellis V, Lund LR, Masucci MT, Moller LB, Olson DP, Pedersen N, Ploug M, et al. 1990. The urokinase receptor and regulation of cell surface plasminogen activation. Cell Differ Dev 32(3):247-253.
15. Calonghi N, Cappadone C, Pagnotta E, Boga C, Bertucci C, Fiori J. Tasco G, Casadio R, Masotti L. 2005. Histone deacetylase 1: A target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer. J Lipid Res 46(8):1596-1603.
16. Cher ML, Biliran HR, Jr., Bhagat S, Meng Y, Che M, Lockett J, Abrams J, Fridman R, Zachareas M, Sheng S. 2003. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci USA 100(13):7847-7852.
17. Cook JA, Gius D, Wink DA, Krishna MC, Rueso A, Mitchell JB. 2004. Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol 14(3):259-266.
18. Cubellis MV, Nolli ML, Cassani G, Blasi F. 1986. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem 261(34):15819-15822.
19. Dallas SL, Rosser JL, Mundy GR, Bonewald LF. 2002. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 277(24):21352-21360.
20. Dietmaier W, Bettstetter M, Wild PJ, Woenckhaus M, Rummele P, Hartmann A, Dechant S, Blaszyk H, Pauer A, Klinkhammer-Schalke M, Hofstadter F. 2006. Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer. Int J Cancer 118(9):2247-2254.
21. Falcone DJ, McCaffrey TA, Haimovitz-Friedman A, Vergilio JA, Nicholson AC. 1993. Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation. J Biol Chem 268(16):11951-11958.
22. Festuccia C, Giunciuglio D, Guerra F, Villanova I, Angelucci A, Manduca P, Teti A, Albini A, Bologna M. 1999. Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion. Oncol Res 11(1):17-31.
23. Festuccia C, Angelucci A, Gravina GL, Villanova I, Teti A, Albini A, Bologna M. 2000. Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells. Int J Cancer 85(3):407-415.
24. Finnin MS, Donigian JR, Pavletich NP. 2001. Structure of the histone deacetylase SIRT2. Nat Struct Biol 8(7):621-625.
25. Futscher BW, Oshiro MM, Wozniak RJ, Holtan N, Hanigan CL, Duan H, Domann FE. 2002. Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet 31(2):175-179.
26. Gao F, Shi HY, Daughty C, Cella N, Zhang M. 2004. Maspin plays an essential role in early embryonic development. Development 131(7):1479-1489.
27. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, Carmeliet P. 1999. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5(10):1135-1142.
28. Jiang N, Meng Y, Zhang S, Mensah-Osman E, Sheng S. 2002. Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene 21(26):4089-4098.
29. Kelly WK, Marks PA. 2005. Drug insight: Histone deacetylase inhibitors-Development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2(3):150-157.
30. Kim DH, Yoon DS, Dooley WC, Nam ES, Ryu JW, Jung KC, Park HR, Sohn JH, Shin HS, Park YE. 2003. Association of maspin expression with the high histological grade and lymphocyte-rich stroma in early-stage breast cancer. Histopathology 42(1):37-42.
31. Koutsilieris M. 1993. Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 13(2):443-449.
32. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C. 2002. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. Embo J 21(11):2672-2681.
33. Li X, Yin S, Meng Y, Sakr W, Sheng S. 2006. Endogenous Inhibition of Histone Deacetylase 1 (HDAC1) by Tumor Suppressive Maspin. Cancer Research (in press).
34. Liu J, Yin S, Reddy N, Spencer C, Sheng S. 2004. Bax mediates the apoptosis-sensitizing effect of maspin. Cancer Res 64(5):1703-1711.
35. Lonardo F, Li X, Siddiq F, Singh R, Al-Abbadi M, Pass HI, Sheng S. 2005. Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer 51:31-39.
36. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. 2001. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1(3):194-202.
37. Martin KJ, Kritzman BM, Price LM, Koh B, Kwan CP, Zhang X, Mackay A, O'Hare MJ, Kaelin CM, Mutter GL, Pardee AB, Sager R. 2000. Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Res 60(8):2232-2238.
38. Maru Y, Hirosawa H, Shibuya M. 2000. An oncogenic form of the Flt-1 kinase has a tubulogenic potential in a sinusoidal endothelial cell line. Eur J Cell Biol 79(2):130-143.
39. McGowen R, Biliran H, Jr., Sager R, Sheng S. 2000. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Res 60(17):4771-4778.
40. Nielsen LS, Kellerman GM, Behrendt N, Picone R, Dano K, Blasi F. 1988. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem 263(5):2358-2363.
41. Pepper MS. 2001. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21:1104-1117.
42. Pillai R, Coverdale LE, Dubey G, Martin CC. 2004. Histone deacetylase 1 (HDAC-1) required for the normal formation of craniofacial cartilage and pectoral fins of the zebrafish. Dev Dyn 231(3):647-654.
43. Ploug M, Kjalke M, Ronne E, Weidle U, Hoyer-Hansen G, Dano K. 1993. Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. J Biol Chem 268:17539-17546.
44. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS. 2005. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280(43):36529-36540.
45. Rabbani SA, Mazar AP. 2001. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 10:393-415.
46. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA. 1998. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95(6):3003-3007.
47. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E, Blasi F. 1990. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9:467-474.
48. Ruden DM, Xiao L, Garfinkel MD, Lu X. 2005. Hsp90 and environmental impacts on epigenetic states: A model for the trans-generational effects of diethyl-stibesterol on uterine development and cancer. Hum Mol Genet 14(1):R149-R155.
49. Schneider SS, Schick C, Fish KE, Miller E, Pena JC, Treter SD, Hui SM, Silverman GA. 1995. A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci USA 92(8):3147-3151.
50. Shao ZM, Nguyen M, Alpaugh ML, O'Connell JT, Barsky SH. 1998. The human myoepithelial cell exerts antiproliferative effects on breast carcinoma cells characterized by p21WAF1/CIP1 induction, G2/M arrest, and apoptosis. Exp Cell Res 241(2):394-403.
51. Sheng S. 2001. The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev 20:287-296.
52. Sheng S. 2004. The promise and challenge toward the clinical application of maspin in cancer. Front Biosci 9:2733-2745.
53. Sheng S, Pemberton PA, Sager R. 1994. Production, purification, and characterization of recombinant maspin proteins. J Biol Chem 269(49):30988-30993.
54. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ, Sager R. 1996. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci USA 93(21):11669-11674.
55. Sheng S, Truong B, Fredrickson D, Wu R, Pardee AB, Sager R. 1998. Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc Natl Acad Sci USA 95(2):499-504.
56. Sherman JM, Stone EM, Freeman-Cook LL, Brachmann CB, Boeke JD, Pillus L. 1999. The conserved core of a human SIR2 homologue functions in yeast silencing. Mol Biol Cell 10(9):3045-3059.
57. Silverman GA, Bartuski AJ, Cataltepe S, Gornstein ER, Kamachi Y, Schick C, Uemura Y. 1998. SCCA1 and SCCA2 are proteinase inhibitors that map to the serpin cluster at 18q21.3. Tumour Biol 19(6):480-487.
58. Spring P, Nakashima T, Frederick M, Henderson Y, Clayman G. 1999. Identification and cDNA cloning of headpin, a novel differentially expressed serpin that maps to chromosome 18q. Biochem Biophys Res Commun 264(1):299-304.
59. Sun J, Rose JB, Bird P. 1995. Gene structure, chromosomal localization, and expression of the murine homologue of human proteinase inhibitor 6 (PI-6) suggests divergence of PI-6 from the ovalbumin serpins. J Biol Chem 270(27):16089-16096.
60. Ustach CV, Kim HR. 2005. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol 25(14):6279-6288.
61. Vassalli JD, Baccino D, Belin D. 1985. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100(1):86-92.
62. Wade PA. 2001. Transcriptional control at regulatory checkpoints by histone deacetylases: Molecular connections between cancer and chromatin. Hum Mol Genet 10(7):693-698.
63. Xia W, Lau YK, Hu MC, Li L, Johnston DA, Sheng S, El-Naggar A, Hung MC. 2000. High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene 19(20):2398-2403.
64. Yin S, Li X, Meng Y, Finley RL, Jr., Sakr W, Yang H, Reddy N, Sheng S. 2005. Tumor-suppressive Maspin Regulates Cell Response to Oxidative Stress by Direct Interaction with Glutathione S-Transferase. J Biol Chem 280(41):34985-34996.
65. Yin S, Lockett J, Meng Y, Biliran H, Jr., Blouse GE, Li X, Reddy N, Zhao Z, Lin X, Anagli J, Cher ML, Sheng S. 2006. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Cancer Res 66(8):4173-4181.
66. Zhang M, Magit D, Sager R. 1997. Expression of maspin in prostate cells is regulated by a positive ets element and a negative hormonal responsive element site recognized by androgen receptor. Proc Natl Acad Sci USA 94(11):5673-5678.
67. Zhang M, Volpert O, Shi YH, Bouck N. 2000. Maspin is an angiogenesis inhibitor. Nat Med 6(2):196-199.
68. Zhou Q, Melkoumian ZK, Lucktong A, Moniwa M, Davie JR, Strobl JS. 2000. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J Biol Chem 275(45):35256-35263.
69. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E, Sager R. 1994. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263(5146):526-529.
70. Zou Z, Zhang W, Young D, Gleave MG, Rennie P, Connell T, Connelly R, Moul J, Srivastava S, Sesterhenn I. 2002. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation. Clin Cancer Res 8(5):1172-1177.